Search | Clinical Trials Finder

Conditions: Cardiogenic Shock
Interventions: Interscalene Block, PECS II Block, Superficial Cervical Plexus Block; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Covid19
Interventions: sotrovimab; Biological
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more

Conditions: Metastatic Colorectal Cancer
Interventions: Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803, SX-682; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ulcerative Colitis
Interventions: 75mg SHP647 (PF-00547659), 225mg SHP647 (PF-00547659); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 29
States / cities: Scottsdale, Arizona • La Jolla, California • Orange, California + 26 more

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine, Trivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 531 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Atlanta, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more

Conditions: Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis
Interventions: Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation); Combination Product
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Influenza, Influenza Vaccines
Interventions: Influenza A (H5N1) Virus monovalent vaccine, Saline placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 842 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 11
States / cities: Paramount, California • Sacramento, California • Newton, Kansas + 8 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 583 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Baltimore, Maryland • Kansas City, Missouri • St Louis, Missouri + 6 more

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 323 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: Conway, Arkansas • Little Rock, Arkansas • Sacramento, California + 14 more

Conditions: Hip Pain Chronic
Interventions: Transmuscular Quadratus Lumborum Block, Pericapsular injection, Bupivacaine Hydrochloride; Procedure · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Atropine Bioequivalence
Interventions: Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL); Drug
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Idiopathic CD4 T Cell Lymphocytopenia
Interventions: Gardasil 9; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Fluarix, Fluzone; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 35 Months
Enrollment: 3,317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more

Conditions: Arthroplasty, Replacement, Knee, Nerve Block
Interventions: Adductor Canal Block, Bupivacaine, Femoral Nerve Block, Bupivacaine; Procedure
Lead sponsor: George Macrinici; Other
Eligibility: 40 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Joliet, Illinois

Conditions: Meningococcal Disease
Interventions: MenACWY-CRM, DTaP-IPV/Hib, HBV, PCV, MMR; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 55 Days to 89 Days
Enrollment: 529 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 42
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more

Conditions: Influenza, Human
Interventions: Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 6 Months to 59 Months
Enrollment: 2,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 39
States / cities: Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 27 more

Conditions: RSV Infection
Interventions: Clesrovimab; Biological
Lead sponsor: Emory University; Other
Eligibility: Up to 8 Months
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza
Interventions: Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 3,027 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Sacramento, California • Boca Raton, Florida • Wichita, Kansas + 10 more

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Post Traumatic Stress Disorder (PTSD)
Interventions: Stellate Ganglion Block injection with ropivicane, Placebo Procedure; Procedure
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Osteoarthitis, Osteoarthritic Knee Pain, Osteoarthritis (OA), Osteoarthritis (OA) of the Knee, Osteoarthritis in the Knee
Interventions: Anteromedial Injection, Anterolateral Injection; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Bolingbrook, Illinois • Chicago, Illinois • La Grange, Illinois + 2 more

Conditions: Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions: Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 585 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 43
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more

Conditions: Knee Osteoarthritis
Interventions: Pulse Radiofrequency, Standard of Care Intra- Articular Injection, Placebo Intra-Articular Injection; Procedure
Lead sponsor: Center For Interventional Pain and Spine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Exton, Pennsylvania

Search by objective public record fields.

Awake Axillary Impella 5.5 Placement - A Feasibility Trial

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Long-Term Safety Of PF-00547659 In Ulcerative Colitis

Sanofi Pasteur, TIV + H1N1, Pediatric Population

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

Transmuscular Quadratus Lumborum Block Plus Pericapsular Injection vs Pericapsular Injection

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

Study to Evaluate ACB Versus FNB Early Postoperative Period Functional Outcomes After TKA

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

A Randomized, Placebo-Controlled Trial of Stellate Ganglion Block in the Treatment of Post Traumatic Stress Disorder

Patient Pain and Function in Medial Knee Osteoarthritis After Anteromedial vs Anterolateral Intra-Articular Corticosteroid Injection

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis